BioSpace News Archive

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

23andMe Holding Co. reported its financial results for the third quarter of its fiscal year 2023, which ended December 31, 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February 14-16, 2023.

Align Technology, Inc. announced that after nearly six years with Align, Yuval Shaked, executive vice president and managing director of iTero scanner and services, has decided to leave the company for personal reasons and spend more time with his family.

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced that it has priced its underwritten public offering.

Sequana Medical NV announces the successful completion of its GLP animal studies, demonstrating the safety of its second-generation DSR product, following chronic exposure.

RELIEF THERAPEUTICS Holding SA, provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statement on Form F-1 initially filed with the United States Securities and Exchange Commission on Aug. 23, 2022 in order to explore alternative options for financing, including non-dilutive sources of capital, with the goal of listing its ordinary shares on the Nasdaq Stock Market.

Biovica International Biovica, active in cancer monitoring, announces that the company’s test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market.

Shanghai MicuRx Pharmaceutical Co., Ltd. announced recently that it has appointed Regis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, MicuRx Pharmaceuticals, Inc.

Enzolytics, Inc. announced today the preliminary results of Toxicology studies of the Company’s ITV-1 anti-HIV therapeutic confirming that the therapy is non-toxic and demonstrating the safety of administration of this patented proprietary immunotherapy.